Nuvalent, Inc.
NUVL$2.60B
Mid CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCAMBRIDGE
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Sep 26, 2026
28wMarket Overview
Stock performance and key metrics
NUVL News
Catalyst Timeline
1 upcoming, 1 past
Drug Pipeline
Neladalkib (NVL-655)
Non-small Cell Lung Cancer
Zidesamtinib (NVL-520)
Locally Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Neladalkib (NVL-655) | Phase 3 | Non-small Cell Lung Cancer | - | - |
Zidesamtinib (NVL-520) | Phase 2 | Locally Advanced Solid Tumor | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply